Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
The biosimilar Ustekinumab has been developed and manufactured by the company
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
This transaction is the third acquisition by three different Japanese players in this segment
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Subscribe To Our Newsletter & Stay Updated
